The Mindera platform can help predict the appropriate biologic drug for a patient prior to therapeutic selection and treatment.

Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. 

She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical care team. Previously, Deren-Lewis was Founder and Principal of Two Blue Consulting working with a variety of clients in the medical and consumer goods industries. She also holds boards seats with Afecta Phramaceuticals and Yorkshire Square Brewery. She was one of the first non-dermatologists to become a member of the American Academy of Dermatology.

At Mindera, Deren-Lewis will lead the company's commercial launch and growth plan for its Mind.Px, the organization's flagship test to prospectively predict a patient's response to expensive biologic drugs for psoriasis and other skin conditions. Her primary initiatives will include building out the company's systems and processes to maximize efficiencies, expanding the commercialization team to position Mind.Px for rapid adoption, and pioneering educational efforts with key opinion leaders in the dermatology industr

"Ann has the demonstrated ability and distinct set of skills to support Mindera's efforts to shape the era of digital predictive skin analytics and lead the market in Dermal Intelligence," says George Mahaffey, CEO of Mindera, in a news release. "Her experience in commercializing medical and aesthetic products and services, with an emphasis on psoriasis, is a perfect fit with our needs."

"I have a passion for moving the needle on novel technologies," adds Deren-Lewis. "The Mindera platform is one of the most innovative platforms I've seen and truly holds the potential to improve patient outcomes and decrease cost of care, and I am thrilled to be a part of the company."